Get started
Author

Chun Loo Gan

Observed names: C. Gan, C.L. Gan, Chun Gan, Chun L. Gan, Chun-Loo Gan, Chun Loo Gan
Observed institutions: The Royal Melbourne Hospital, University of Calgary, Royal Brisbane and Women's Hospital, Monash Health, Austin Health, Olivia Newton-John Cancer Research Institute
ORCID: 0000-0003-2576-9310
Observed ORCID: 0000-0003-2576-9310
OpenAlex ID: A5000275497
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
2021 · Shaan Dudani, Guillermo de Velasco, et al. · JAMA Network Open · 342
PDF
Integrative clinical and molecular characterization of translocation renal cell carcinoma
2022 · Ziad Bakouny, Ananthan Sadagopan, et al. · Cell Reports · 124
PDF
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium
2022 · Ziad Bakouny, Talal El Zarif, et al. · European Urology · 116
PDF
Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
2022 · Nicholas A. Bosma, Matthew T. Warkentin, et al. · European Urology Open Science · 104
PDF
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial
2021 · Edmond M. Kwan, Lavinia Spain, et al. · European Urology · 87
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials
2021 · Chun L. Gan, Igor Stukalin, et al. · European Journal of Cancer · 49
PDF
Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
2021 · Chun Loo Gan, Shaan Dudani, et al. · Cancer Medicine · 42
PDF
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
2022 · Jeffrey Graham, John Connor Wells, et al. · European Journal of Cancer · 36
Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
2020 · Shaan Dudani, Guillermo de Velasco, et al. · Journal of Clinical Oncology · 34
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis
2021 · Daniel V. Araujo, J. Connor Wells, et al. · Journal of Geriatric Oncology · 27
Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.
2020 · Ziad Bakouny, Wanling Xie, et al. · Journal of Clinical Oncology · 21
New insights into the obesity paradox in renal cell carcinoma
2020 · Chun Loo Gan, Daniel Y. C. Heng · Nature Reviews Nephrology · 18
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
2022 · Chun Loo Gan, Jiaming Huang, et al. · European Urology Oncology · 15
The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).
2021 · Andrew Lachlan Schmidt, Wanling Xie, et al. · Journal of Clinical Oncology · 14
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study
2021 · J. Connor Wells, Shaan Dudani, et al. · Clinical Genitourinary Cancer · 13
PDF
Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future
2020 · Chun Loo Gan, Shaan Dudani, et al. · The Cancer Journal · 12
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
2021 · Chun Loo Gan, Shaan Dudani, et al. · Journal of Clinical Oncology · 11
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
2020 · Shaan Dudani, Chun Loo Gan, et al. · Journal of Clinical Oncology · 10
Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
2020 · Igor Stukalin, Shaan Dudani, et al. · Journal of Clinical Oncology · 8
Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials
2019 · Crescens Tiu, Zoe Loh, et al. · Oncology · 6
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma
2022 · Akram M. Shayeb, Hannah Dzimitrowicz McManus, et al. · Clinical Genitourinary Cancer · 5
68Ga‐prostate‐specific membrane antigen (PSMA) PET/CT as a clinical decision‐making tool in biochemically recurrent prostate cancer
2021 · Amy Davies, Marcus Foo, et al. · Asia-Pacific Journal of Clinical Oncology · 5
PDF
Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
2021 · Jeffrey Graham, Connor Wells, et al. · Journal of Clinical Oncology · 4
Case – Acquired hemophilia A in a patient with metastatic castration-resistant prostate cancer
2021 · Michael Poscente, Chun Loo Gan, et al. · Canadian Urological Association Journal · 4
PDF
Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
2020 · Chun Loo Gan, Shaan Dudani, et al. · Journal of Clinical Oncology · 4
Works count: 40
Citation count: 1,129
H-index: 14
I10-index: 18
Year
Topic
Type